The Alexandra’s Law Act of 2025 would authorize federal courts to issue an advisory statement in select controlled substances cases, specifically where a death occurred in connection with an offense involving a fentanyl analogue. The bill adds new language to Section 401 of the Controlled Substances Act to direct the court to inform the defendant that death may trigger homicide liability under federal law and to outline the penalties and caveats associated with drug-related offenses.
Beyond the advisory, the bill creates and enriches evidentiary pathways: prior convictions or guilty pleas related to fentanyl or its analogues may be used to show knowledge that the substance provided to the decedent contained fentanyl, and sworn statements may be admitted across state and federal courts under aligned conditions. There is an explicit exception for prosecutions involving individuals who were minors at the time of the offense.
The policy aim is to clarify liability and align trial tactics with the deaths associated with fentanyl analogues, while preserving certain safeguards for underage offenders.
At a Glance
What It Does
Adds a new advisory statement to CSA Section 401(i) in cases where death occurred in connection with a fentanyl analogue offense, and creates cross-jurisdiction evidentiary rules around related statements.
Who It Affects
Defendants charged under CSA 401(i) involving fentanyl analogues with death, courts issuing the advisory, prosecutors, and trial teams; juries that assess knowledge and intent.
Why It Matters
This sets a formal warning and evidentiary framework for lethal drug cases, potentially influencing charges and trial strategy by clarifying when homicide liability can attach and how prior drug-conviction history may be used.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new subsection to the Controlled Substances Act that requires a court to give a defendant an advisory statement when the case involves a fentanyl analogue and a death. The warning is designed to inform the defendant about the possible homicide consequences and to explain the danger posed by illicit drugs—especially when mixed with fentanyl.
The intent is to create a clearer, more informed trial posture for cases where drug distribution or sale ends in a death.
In addition to the advisory, the bill permits the use of prior convictions or guilty pleas relating to fentanyl or its analogues as evidence of the defendant’s knowledge that the substance provided to the decedent contained fentanyl. It also creates mechanisms for the admission of sworn statements across federal and state courts, helping to unify evidentiary standards.
An important limit is that the advisory provisions do not apply to prosecutions of individuals who were minors at the time of the offense. The overall effect is to codify a transparent, cross-jurisdictional evidentiary framework around fentanyl-related deaths, while balancing due process protections for younger offenders.
The Five Things You Need to Know
The bill adds an advisory statement to CSA Section 401(i) for deaths related to fentanyl analogue offenses.
A defendant in such cases may face homicide charges under 18 U.S.C. 1111 or 1112 if death occurs.
The court must inform the defendant of the dangers of illicit drugs and the potential liability in future actions.
Prior fentanyl-related convictions or pleas may be used to show knowledge of fentanyl content in the substance provided.
There is an exception for prosecutions involving individuals who were minors at the time of the offense.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Controlled Substances Advisory Statement Created
Section 2 adds new language to the CSA, requiring an advisory statement when a death occurs in the context of an offense involving a fentanyl analogue. This creates a formal, court-delivered notice that can shape how defendants and juries understand liability in specific narcotics cases.
Advisory Content
The advisory clarifies that a conviction or guilty/no contest plea in these offenses may lead to homicide liability, and it explicitly warns about the dangers of illicit drugs and fentanyl analogues and the potential for enhanced charges if death results.
Evidence and Admissibility
The bill authorizes using prior convictions or pleas related to fentanyl analogues to prove knowledge that the substance contained fentanyl. It also sets cross-jurisdiction admissibility provisions, enabling sworn statements to be admitted in federal and state courts under specified conditions.
Minor Exception
Paragraph (4) provides that the advisory and related evidentiary provisions do not apply to prosecutions of individuals who were minors at the time of the offense, limiting the reach of the new framework in juvenile cases.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal prosecutors handling fentanyl analogue cases may gain clearer leverage and evidentiary paths.
- Courts issuing standardized advisory instructions may achieve greater consistency in trial proceedings.
- Public health and victim-advocacy groups focused on fentanyl harm may welcome clearer messaging and accountability.
- Law enforcement investigates distribution networks with a potential link to fatal outcomes, improving case presentation.
Who Bears the Cost
- Defendants facing new advisory instructions and potential homicide implications.
- Defense counsel who must navigate the advisory and cross-jurisdiction evidence rules.
- Courts and court staff tasked with implementing and evidentiary requirements.
- Prosecutors who must manage more complex evidentiary issues and coordination across jurisdictions.
Key Issues
The Core Tension
The central dilemma is whether imposing a formal advisory and broad evidentiary use in fentanyl-death cases improves accountability and deterrence without unduly expanding homicide liability or complicating trial outcomes through cross-jurisdictional evidentiary rules.
The bill’s design hinges on the balance between clear, warn-and-know messaging and the risks of expanding liability in drug-death cases. While the advisory statement could improve transparency and jury understanding, it raises questions about how youthful offenders are treated and how cross-jurisdictional evidence will be applied consistently.
The scope of “analogue” substances and the potential breadth of admissible statements may also create implementation challenges for judges, prosecutors, and defense teams alike.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.